Late-stage COPD candidate aclidinium could transform mid-sized Almirall. This is what’s exciting the dozen or more analysts that cover such long-acting muscarinic antagonists; it’s the potential $2 billion drug that “could double or treble the size of this company in a very short time,” sums up one analyst. At the same time, the newly-listed company's other challenge is to monetize the fruits of its primary-care-focused R&D in a world that's going specialist.
Melanie Senior
Spain’s Almirall SA may have listed only 30% of its share capital at its June 2007 IPO, but the...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
